Aravive (NASDAQ:ARAV) is taking a differentiated approach with its lead molecule, batiraxcept, to target inhibition of the GAS6/AXL signaling pathway in several cancer indications.
POINT Biopharma Global (NASDAQ:PNT) is accelerating the development of precision medicines for the treatment of cancer, with a late- and early-stage pipeline of radiopharmaceuticals, a technology platform for pipeline...
ENDRA Life Sciences (NASDAQ:NDRA) has developed a novel assessment tool – Thermo Acoustic Enhanced Ultrasound (TAEUS) – to enhance existing ultrasound systems and provide capabilities that are available with MRI, but at...
Closely-held Illuminate Health is leveraging a technology-enabled continuous medication management platform to help patients optimize medications at home to improve treatment adherence and reduce hospitalizations.
Annovis Bio (NYSE:ANVS) is developing a lead drug candidate, ANVS401, to inhibit more than one neurotoxic protein, improving the information highway of nerve cells, known as axonal transport, for the treatment of...
Rani Therapeutics (NASDAQ:RANI) is developing a disruptive technology to solve the problem of converting biologic injectable drugs, including antibodies, peptides and proteins, into oral therapies with its RaniPill that...
As a co-founder and CEO of closely-held Cellares, which is pioneering an automated approach to cell therapy manufacturing, Fabian Gerlinghaus, an aerospace engineer by training, made the switch to biotech eight years...
As a research assistant professor at the Department of Pharmacology at the University of Washington, Dr. Ben Land, Ph.D. is broadly interested in how cannabinoids and opioids mediate pain and reward. But in a...
NervGen Pharma (TSX-V:NGEN; OTCQX:NGENF) is developing a new class of drugs that repairs damage to the nervous system and restores motor, sensory and cognitive function to diseases where there are currently no approved...
Recently launched Lanier Biotherapeutics is developing specialty biologic treatments for indications in multifunctional retina, dermatology and Type 2 inflammation diseases.
Even though a number of antiviral medications are in use to treat chronic hepatitis B virus (HBV) infections, Aligos Therapeutics (NASDAQ:ALGS) is going one step further with a portfolio of drug candidates in clinical...
After a failed Phase 3 trial in August 2020 with its CaPre lead drug candidate for patients with severe hypertriglyceridemia, Acasti Pharma (NASDAQ, TSXV:ACST) has transitioned into the rare and orphan disease sector...
In a bid to counter the next great health crisis, ContraFect (NASDAQ:CFRX) is in late-stage development of a new modality to treat life-threatening and antibiotic-resistant infections, using direct lytic agents (DLAs).
Aptevo Therapeutics (NASDAQ:APVO) has developed a broad portfolio of potential immuno-oncology therapies with multiple mechanisms of action from two differentiated bispecific and multi-specific antibody platform...
With an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease, ReShape Lifesciences (NASDAQ:RSLS) is reshaping patients minds, bodies and lives.
UNITY Biotechnology’s (NASDAQ:UBX) current focus is on developing medicines to selectively eliminate or modulate senescent cells and to provide transformative benefit in age-related ophthalmologic and neurologic...
Closely-held Bombi Biomics of the Netherlands has developed a technology known as Bombilysin with the potential to kill bacteria from the outside shell in contrast to conventional antibiotics that typically are intended...
Anebulo Pharmaceuticals (NASDAQ:ANEB) is developing a novel antidote for cannabinoid intoxication and, longer term, other indications related to abuse and addiction.
Lucid Psycheceuticals’ next generation approach to total brain health is targeting the interface between mental health and neurodegenerative disorders with therapeutic products inspired by psychedelics and new chemical...
As a co-founder, chairman and CEO of Sigyn Therapeutics (pronounced Sig-en) (OTCMarkets:SIGY), a medical device company developing a blood purification system to treat life-threatening inflammatory conditions, including...
Altamira Therapeutics (NASDAQ:CYTO) is using its recent acquisition of closely-held Trasir Therapeutics as a steppingstone for a strategic repositioning to focus on development of RNA therapeutics, while in the medium...